Arvinas’ ASCO Abstract Data May Have Been Misunderstood

Summary: Arvinas recently revealed their ASCO abstract which included first-in-human efficacy and safety data for their leading drug, ARV-110. The initial market response was negative (ARVN -25%) but the data appears to have been widely misinterpreted secondary to high expectations. ARV-110, as monotherapy, induced a 25% (2/8) response rate in doses shown to be tumor-inhibiting […]
To access this post, you must purchase Prime Membership.

This information is protected.

%d bloggers like this: